Skip to main content

Advertisement

Table 1 Summary of the 14 observational studies assessing the treatment outcomes for patients with MDR-TB under DOTS-Plus that were included in the meta-analysis (n = 14)

From: Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies

Study authors Study location Study period Study design Sample size HIV (%) Treatment duration Treatment regimen
Kurbatova et al. [16] Five countriesa 2000–2003 RC 1768 1.6   Individualized
Singla et al. [17] India 2002–2006 RC 126 24–27 months Standardized
Keshavjee et al. [18] Russia 2000–2004 RC 579 0.9 ≥24 months Individualized
Riekstina et al. [19] Latvia 2002 RC 75 24 months Individualized
Cox et al. [20] Karakalpakstan, Uzbekistan 2003–2005 PC 87 ≥24 months Individualized
Shin et al. [21] Russia 2000–2002 RC 244 0 ≥12 months Individualized
Holtz et al. [22] Latvia 2000 RC 167 12–18 months after conversion Individualized
Leimane et al. [23] Latvia 2000 RC 204 0.5 12–18 months after conversion Individualized
Tupasi et al. [24] Philippines 1999–2002 PC 149 ≥24 Months Individualized
Arora et al. [25] India 2002–2005 RC 52 24 months Standardized
Mitnick et al. [26] Peru 1999–2002 RC 651 1.5 15 months after conversion Standardized
Jain et al. [27] India 2009 PC 130 24 months Standardized
Farley et al. [28] South Africa 2000–2004 PC 757 38 12–18 months after conversion Standardized
Van Deun et al. [14] Bangladesh 1997–1999 RC 58 24 months Standardized
  1. aThe five countries were Peru, Latvia, Estonia, Russia, and the Philippines